Printer Friendly
The Free Library
14,670,786 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

New PhotoDynamic Therapy Market Study Predicts Growth Rate.


Business Editors & Health/Medical Writers

MISSION VIEJO, Calif.--(BUSINESS WIRE)--Nov. 27, 2000

Non-ophthalmic PDT PDT
abbr.
Pacific Daylight Time


PDT Pacific Daylight Time

PDT n abbr (US) (= Pacific Daylight Time) → hora de verano del PacĂ­fico

PDT 
 markets collectively rival the high-growth rate ophthalmic segment, according to a new report published by Medical Insight, Inc. this month. "Our conservative estimates of drug sales reveal over $700 million of revenues (during the five year forecast period) related to drugs that are currently under commercial development," said report author and medical industry analyst Michael Moretti.

According to Moretti, "Related sales of diode lasers used in these treatments are estimated at more than 2,500 systems generating over $170 million. In addition, the disposable fiberoptic light delivery devices used in PDT procedures will produce more than $80 million in revenues for this developing industry. Thus, the total market for PDT drugs and devices during this forecast period is estimated at close to $1 billion."

Although there are six major PDT drug development companies discussed in this report, the supply of lasers and fibers is limited to only three manufacturers: Diomed Inc., Coherent Medical, and Laserscope. Of these three suppliers, only the privately held Diomed (Andover, Mass.) manufactures the diode laser systems which will be used in the majority of future non-ophthalmic PDT treatments. "Currently, we estimate that Diomed has installed approximately 100 diode lasers for PDT, and has pending orders for another 200 units," said Moretti. Diomed also exclusively supplies fiber delivery devices, via patent licensing and supply arrangements with PDT companies, including Axcan.

Public companies participating in the PhotoDynamic Therapy Market include: Axcan Pharma (Nasdaq:AXCA); DUSA DUSA Deputy Under Secretary of the Army
DUSA Deakin University Student Association
DUSA Dundee University Students' Association (Scotland)
DUSA Designated Unclassified Subject Area
 (Nasdaq:DUSA); Coherent Medical (Nasdaq:COHR COHR Congolese Observatory of Human Rights ); Laserscope (Nasdaq:LSCP LScP left scapuloposterior (position of fetus). ); Mirivant (Nasdaq:MRVT MRVT Materiel Release Verification Test ); Pharmacyclics (Nasdaq:PCYC PCYC Police Citizens Youth Club
PCYC Palmer's Cove Yacht Club (Salem, Massachusetts)
PCYC Perche Creek Yacht Club (Columbia, Missouri) 
); and QLT QLT Quadra Logic Technologies
QLT Quick Link Text
 (Nasdaq:QLTI).

To obtain a copy of The PhotoDynamic Therapy Market Study, contact Michael Moretti at: Morettim@aol.com or call (949) 367-8095.

Keywords: Medical Lasers, Dermatology, Cancer, Oncology, Medical Devices, PDT, Photodynamic Therapy
COPYRIGHT 2000 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 27, 2000
Words:304
Previous Article:Neoforma Signs Major Suppliers to Marketplace@Novation; Suppliers Include Kimberly-Clark, Kodak, Marconi HCP, Shared Service Systems and Standard...
Next Article:Global Water Technologies Awarded Additional $10 Million in Power Industry Contracts.
Topics:



Related Articles
Shedding light on cancer: doctors fight malignancies with photoactive dyes.
PDT Inc. shareholders to vote on stock split.
DUSA Pharmaceuticals reports 90 - 100% efficacy in Phase II clinical trial results.
PDT Inc. announces first-quarter results and clinical trial update.
FDA Advisory Committee Recommends Approval of Photodynamic Therapy for Early-Stage Lung Cancer Treatment.
BlueStone Capital Partners Initiates Coverage on Laserscope With a HOLD Rating.
FDA Approves Photodynamic Therapy for Advanced Lung Cancer Using Laserscope's PDT Laser Systems.
PHOTOCURE SIGNS NEW PACT WITH NORWEGIAN RADIUM HOSPITAL.
Elsevier launches new journals and engineering info service.(Brief Article)
Photodynamic therapy and endoscopic mucosal resection for Barrett's dysplasia and early esophageal adenocarcinoma.(Original Article)

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles